

HOLLIS EDEN PHARMACEUTICALS INC /DE/

Form 8-K

November 09, 2004

---

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

---

**FORM 8-K**

---

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the**

**Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): November 9, 2004**

---

**HOLLIS-EDEN PHARMACEUTICALS, INC.**

(Exact name of registrant as specified in its charter)

---

**Delaware**

(State or other jurisdiction of incorporation)

**000-24672**  
(Commission File No.)

**13-3697002**  
(IRS Employer Identification No.)

Edgar Filing: HOLLIS EDEN PHARMACEUTICALS INC /DE/ - Form 8-K

**4435 Eastgate Mall, Suite 400**

**San Diego, California 92121**

(Address of principal executive offices and zip code)

**Registrant's telephone number, including area code: (858) 587-9333**

**Not Applicable.**

(Former name or former address, if changed since last report)

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

---

**ITEM 2.02. RESULTS OF OPERATIONS AND FINANCIAL CONDITIONS.**

On November 9, 2004, Hollis-Eden Pharmaceuticals, Inc., a Delaware corporation, issued a press release reporting its earnings for the third quarter ended September 30, 2004. See Exhibit 99.1 for the text of the press release.

**ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS.**

**EXHIBITS.**

99.1 Press release issued on November 9, 2004 by Hollis-Eden Pharmaceuticals, Inc.

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**HOLLIS-EDEN PHARMACEUTICALS, INC.**

Dated: November 9, 2004

By: /s/ Eric J. Loumeau

---

Eric J. Loumeau  
Vice President, General Counsel

**INDEX TO EXHIBITS**

99.1 Press Release issued on November 9, 2004 by Hollis-Eden Pharmaceuticals, Inc.